While nonprostatic PSMA uptake hampers accuracy in prostate cancer staging, it also expands potential applications of PSMA PET, which as a result has been proposed for staging and restaging of other malignancies such as RCC [32, 33]. Here, FOLH1 is linked to prostate carcinoma.